Amgen disclosed on its April 30, 2026 earnings call that the Phase 3 MARITIME program now includes a 300-patient SWITCH study designed for one specific population: patients already on weekly semaglutide or tirzepatide who would transition onto MariTide dosed every 8 weeks or quarterly. This is the first late-stage obesity trial that explicitly addresses the maintenance-dosing question rather than treatment-naive induction.
Research-context information only. Peptides and investigational drugs discussed below are research compounds or investigational therapies. Doses and outcomes reported come from published clinical-trial data and company disclosures. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.
What the MARITIME-Switch Study Actually Tests
The SWITCH study design has three structural features that make it different from every other obesity Phase 3 trial reading out before 2028.
Patient population: established weekly GLP-1 users. Enrollment requires patients already on weekly injectable semaglutide or tirzepatide at therapeutic doses. This is the commercial reality the trial is designed to model — more than 2 million US patients started weekly GLP-1 therapy in 2025-2026, and the obesity-drug market is no longer treatment-naive.
Dosing interval: every 8 weeks or quarterly, not monthly. Most MariTide development has been at the monthly schedule. The SWITCH arms test the longer intervals — 4 to 6 injections per year instead of the 12 a monthly schedule requires. The bet is that once a patient has reached a stable weight-loss endpoint on weekly therapy, maintenance dosing may not require the same exposure frequency that induction did.
Primary endpoint: 52-week change in body weight from the switch point. The trial measures whether MariTide holds the line — not whether it produces additional weight loss versus continued weekly therapy. A non-inferiority style readout is the most plausible interpretation, though Amgen has not formally characterized the statistical design.
Amgen CEO Robert Bradway framed the trial design on the earnings call by saying the company would "evaluate switching from medicines which are injected 52 times a year to one which can be injected as few as four or six times a year." That is the entire commercial pitch in one sentence.
Why Maintenance Dosing Is the Next Battleground
The first generation of obesity drug trials measured induction — how much weight a treatment-naive patient could lose. Those trials are essentially decided: retatrutide at 28.7% in TRIUMPH-4, tirzepatide at 20.9% in SURMOUNT-1, semaglutide at 14.9% in STEP 1. Adding new molecules to that competition produces diminishing returns.
Maintenance is unsolved. Real-world adherence to weekly injectable GLP-1s falls to 40-60% within the first year, with injection burden cited as a contributing factor in patient-reported survey data. The economic loss from weight regain in patients who discontinue is enormous — both to the patient and to the payer. A trial that shows successful maintenance on a quarterly schedule reframes the cost-and-convenience math entirely.
Three near-term Phase 3 readouts will set the maintenance-dosing template:
- Lilly's Foundayo (orforglipron) ATTAIN-MAINTAIN already reported in May 2026 that an oral pill can preserve injectable-induced weight loss after a transition. The orforglipron maintenance data showed real but modest weight regain on transition.
- MARITIME-Switch tests whether a much-less-frequent injection can do the same.
- Pfizer's PF-3944 maintenance arms are still in earlier-stage development with no disclosed switch trial.
If MariTide's SWITCH readout shows non-inferior weight maintenance at quarterly dosing, Amgen has a category that no incumbent can directly replicate without a new molecule. Weekly semaglutide and tirzepatide cannot become quarterly drugs through label expansion — the pharmacokinetics do not support it.
What This Changes for Current Weekly GLP-1 Buyers
MariTide will not appear in research peptide vendor catalogs, 503A compounding pharmacies, or branded prescription channels before 2028 at the earliest. The molecule's peptide-antibody conjugate chemistry sits outside what compounders can replicate, and Amgen's patent protection runs into the 2040s. The SWITCH trial design does not affect current weekly protocols.
The strategic signal matters for buyers planning a 2-3 year horizon.
If you are on weekly compounded semaglutide or tirzepatide and tolerating it well, the SWITCH trial does not give you a reason to change anything. Continued weekly therapy at current vendor pricing remains the most cost-effective path. Compare current options at best semaglutide vendors and best tirzepatide vendors.
If you currently inject weekly retatrutide for maximum efficacy, MariTide will not match retatrutide on raw weight-loss numbers — the 28.7% retatrutide ceiling versus MariTide's 20% Phase 2 ceiling is a real gap. MariTide's pitch is convenience, not magnitude. Buyers prioritizing peak efficacy stay with weekly retatrutide.
If injection frequency is the friction point keeping you off therapy, the 2028+ MariTide launch window is too far out to wait. Starting weekly compounded therapy now and re-evaluating at MariTide's eventual launch produces meaningfully more cumulative weight loss than waiting. Most patients in this situation are better served by the lowest-friction weekly option available today — an oral branded semaglutide is one path, weekly compounded semaglutide is another at lower cost. The Wegovy pill vs Foundayo comparison covers the branded oral landscape, and /deals tracks current vendor coupon stacks across the weekly compounded options.
Current vendor pricing on weekly compounded semaglutide, tirzepatide, and retatrutide moves week to week. Discount codes across the recommended vendor list run another 20-50% off list prices.
